Bank of New York Mellon Corp lowered its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 3.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 191,982 shares of the biotechnology company’s stock after selling 7,096 shares during the period. Bank of New York Mellon Corp owned 1.01% of Enanta Pharmaceuticals worth $6,907,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Louisiana State Employees Retirement System bought a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth approximately $205,000. Prudential Financial Inc. raised its position in shares of Enanta Pharmaceuticals by 42.4% in the 1st quarter. Prudential Financial Inc. now owns 69,671 shares of the biotechnology company’s stock worth $2,146,000 after acquiring an additional 20,743 shares in the last quarter. Capstone Asset Management Co. bought a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth approximately $212,000. Weiss Multi Strategy Advisers LLC raised its position in shares of Enanta Pharmaceuticals by 50.0% in the 1st quarter. Weiss Multi Strategy Advisers LLC now owns 30,000 shares of the biotechnology company’s stock worth $924,000 after acquiring an additional 10,000 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Enanta Pharmaceuticals by 9.0% in the 1st quarter. AQR Capital Management LLC now owns 124,054 shares of the biotechnology company’s stock worth $3,820,000 after acquiring an additional 10,260 shares in the last quarter. 66.07% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/bank-of-new-york-mellon-corp-decreases-stake-in-enanta-pharmaceuticals-inc-enta/1600091.html.

Enanta Pharmaceuticals, Inc. (ENTA) opened at 46.80 on Friday. Enanta Pharmaceuticals, Inc. has a 12 month low of $22.17 and a 12 month high of $47.00. The company’s market cap is $893.41 million. The stock has a 50 day moving average price of $41.09 and a 200 day moving average price of $34.67.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.05. The firm had revenue of $7.51 million during the quarter, compared to analyst estimates of $8.08 million. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. Enanta Pharmaceuticals’s quarterly revenue was down 46.3% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.06) earnings per share. Analysts anticipate that Enanta Pharmaceuticals, Inc. will post $1.14 earnings per share for the current fiscal year.

ENTA has been the subject of several research reports. Zacks Investment Research lowered Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, June 21st. JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 target price for the company in a research report on Tuesday, July 11th. BidaskClub lowered Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Robert W. Baird increased their target price on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 8th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a $38.00 target price (up previously from $32.00) on shares of Enanta Pharmaceuticals in a research report on Wednesday, August 9th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $38.00.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.